Skip to main content

Table 3 Total burden scores by socio-demographic and clinical variables

From: The relationship between self-efficacy and treatment satisfaction among patients with anticoagulant therapy: a cross-sectional study from a developing country

Variable

Frequency % N(300)

Median (Q1–Q3)

Mean ± SD

Mean

rank

P-value

Age category (years)

0.651 b

  < 30

31 (10.3)

42.00(34.00–52.00)

41.68 ± 11.02

141.21

 30–60 

163 (54.3)

43.00(37.00–51.00)

43.99 ± 10.77

154.47

  > 60

106 (35.3)

45.00(36.00–50.00)

42.73 ± 91.78

147.11

Gender

0.006 a

 Male 

115 (38.3)

46.00(38.00–52.00)

45.01 ± 9.88

168.03

 Female 

185 (61.7)

42.00(35.00–49.00)

42.25 ± 10.68

139.60

BMIa

0.702 b

 Normal 

65 (21.7)

42.00(35.00–50.00)

42.89 ± 9.89

140.45

 

 Overweight 

136 (45.3)

44.00(36.25–51.75)

43.44 ± 10.15

151.19

 

 Obese 

93 (31.0)

44.00(37.00–50.50)

43.55 ± 11.48

147.04

 

Education

0.160 b

 Illiterate

20 (6.7)

39.00(29.25–49.50)

39.60 ± 11.17

118.63

 Elementary

43 (14.3)

46.00(36.75–50.25)

43.31 ± 9.19

149.86

 Primary

52 (17.3)

42.00(35.00–49.00)

41.06 ± 10.13

131.38

 Secondary

54 (18.0)

45.00(38.75–54.00)

45.67 ± 9.60

165.19

 University

124 (41.3)

43.00(36.00–50.75)

43.80 ± 11.25

146.76

Income (month)

0.001b

 Less than 2000 NIS

23 (7.7)

40.00(31.00–46.00)

38.60 ± 8.74

108.11

 

 2000–5000 NIS

160(53.3)

42.00(35.00–50.00)

41.93 ± 9.44

136.66

 More than 5000 NIS

108(36.0)

45.00(40.00–53.00)

46.06 ± 11.10

167.91

locality

0.123 b

 Camp

36(12.0)

41.00(35.00–48.50)

41.47 ± 8.55

131.01

 Rural

85(28.3)

40.00(34.00–50.00)

41.83 ± 11.09

136.84

 Urban

172(57.3)

44.00(37.25–51.00)

49.17 ± 10.13

155.37

Marital status

0.005a

 Married

229(76.3)

44.00(37.00–51.00)

44.29 ± 10.26

 

 Unmarried (single, divorced, widowed)

67(22.3)

41.00(31.00–49.00)

39.86 ± 10.32

Employment status

0.114 a

 Employed

194(64.7)

42.00(35.75–50.25)

44.76 ± 11.55

158.40

 Unemployed

100(33.3)

45.00(36.25–52.00)

42.61 ± 9.88

141.88

Chronic co-morbid disease

0.696 b

 No co-morbid disease

42 (14.0)

44.00(38.00–52.00)

44.24 ± 8.25

156.31

 One disease

44(14.7)

45.00(35.00–53.00)

44.67 ± 11.45

156.79

 Two diseases

63(21.0)

42.00(36.00–51.00)

42.35 ± 9.26

141.24

 Three diseases or more

146(48.7)

44.00(36.00–50.00)

43.41 ± 11.05

144.93

Indications for anticoagulant

0.366 b

 Atrial fibrillation

63 (21.0)

43.00 (37.00–50.00)

42.54 ± 8.60

145.65

 Deep vein thrombosis or Pulmonary embolism

29 (9.7)

41.00 (34.00–46.50)

41.00 ± 8.41

126.03

 Prophylaxis c

72 (24.0)

44.00 (37.00–52.00)

43.57 ± 10.16

154.79

 Other indications

136 (45.3)

45.00 (36.00–51.00)

44.01 ± 11.71

155.69

Chronic medications

0.932 a

≤4

176(58.7)

43.00(36.00–51.00)

43.43 ± 11.05

150.86

  > 4

124(41.3)

43.00 (36.00–50.00)

43.14 ± 9.57

149.99

Anticoagulant drug

 UHF

87(29)

42.00(35.00–51.00)

42.75 ± 9.63

143.83

0.596 b

 Vit-K dependent

134(44.7)

43.00 (36.00–51.00)

41.65 ± 11.06

143.90

 NOACs

75(25)

44.00 (36.75–57.00)

44.12 ± 11.43

154.06

  1. a The statistical significance of differences was calculated using the Mann-Whitney U test
  2. b The statistical significance of the differences was calculated using the Kruskal-Wallis test
  3. Bold P-value indicates a significant difference
  4. cPatients that received prophylactic doses of unfractionated heparin during hospital admission
  5. NIS: New Israeli Shekel (0.29 US Dollar)